© 2000 European Society of Cardiology
Implantable left ventricular assist systems (LVAS): Recent results. A report from a series of meetings sponsored by the Study Group on Advanced Heart Failure of the Working Group on Heart Failure
a Cardiology, Swiss Cardiovascular Center Bern, University Hospital CH-3010 Bern, Switzerland
b Department of Cardiothoracic Surgery, Muenster University Hospital D-48120, Münster, Germany
c Study Group on Advanced Heart Failure, Secretariat Oxfordshire, OX14 3YT, UK
d Tjadergatan 21, S-42669, Vastra Frolunda, Sweden
e Clinical Cardiology and Heart Failure Unit, Istitute Clinico Humanitas Via Manzoni, 56, 1-20089 Rozzano Milano, Italy
f Group Hospitalier Pitié-Salpêtrière, Service de Cardiologie 47 Boulevard de L'Hôpital, F-75019 ParisCedex 13, France
g Cardiology, University of Vienna Wahringer Gürtel 18-29, A-1090, Vienna, Austria
h Masaryk University, School of Medicine, St Ann's University Hospital Pakarska 53, Brno, 65691, Czech Republic
i Sahlgrenska University Hospital/Östra, Department of Medicine S-41685 Göteborg, Sweden
j Castle Hill Hospital Castle Road, Cottingham, Hull, East Yorkshire, HU16 5JQ, UK
* Tel.: +41-31-632-4464; fax: +41-31-632-4299. E-mail address: paul.mohacsi{at}insel.ch
| Abstract |
|---|
Implantable left ventricular assist systems (LVAS) consist of implantable pumps with small control consoles and power sources that can be worn externally. These systems provide far greater patient mobility and independence than external pumps with bulky control consoles. Patients with implantable LVAS can be discharged from hospital and are able to return to work and resume active sports. Most patients have received these systems as a bridge to heart transplantation. Clinical status and quality of life improve dramatically after device implantation and survival on support (60–70% after approx. 100 days of support) is acceptable compared with transplant candidates on medical therapy. Patient selection and adverse events, primarily bleeding, thromboembolism and infection, are important issues with LVAS. In the future, long-term support and bridging to myocardial recovery may become important indications for LVAS.
Key Words: Advanced heat failure (AHF) Left ventricular assist systems (LVAS) Mechanical circulatory support (MCS)
Received December 6, 1999; Revised December 22, 1999; Accepted December 23, 1999
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. A. Louis, I. R. Manousos, A. P. Coletta, A. L. Clark, and J. G.F. Cleland Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH Eur J Heart Fail, January 1, 2002; 4(1): 111 - 116. [Abstract] [Full Text] [PDF] |
||||
